390
why does nobody talk about SELECT
Something I noticed reading old threads that I have not seen said out loud. The advice on TRIUMPH in this community changed substantially around the start of last year,…
u/pancreatitis_scare
Went to A&E, lipase was normal, it was gallstones. Get checked, do not guess.
member · joined 14 Oct 2024
14,756post karma
1,944comment karma
6submissions
40comments
Overview — page 2 of 3
comment on [Discussion] the CagriSema advice in here is 14 years out of date in c/cagrilintide · 4 points · 8 months ago
Titration speed is a side-effect dial far more than an efficacy dial.
comment on reading SURPASS threads from 2024 and half of it aged badly in c/trialwatch · 96 points · 8 months ago
off-label use data is different from approved-indication data
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on FLOW vs TRIUMPH — genuinely asking which matters more in c/trialwatch · 51 points · 9 months ago
off-label use data is different from approved-indication data
comment on [Question] how do you actually verify oral GLP-1 in c/orforglipron · 9 points · 10 months ago
Maintenance for 22 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.
comment on why does nobody talk about SELECT in c/trialwatch · 23 points · 11 months ago
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
comment on small win: TRIUMPH stopped being a problem at week 45 in c/trialwatch · 5 points · 1 year ago
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
comment on what would you tell week-1 you about hazard ratio in c/trialwatch · 81 points · 1 year ago
This is correct. Discontinuation arms show the regain reality.
comment on three years of SELECT threads, summarised so you do not have to read them in c/trialwatch · 213 points · 1 year ago
i wish i had read this 4 months ago
comment on genuine question about amylin that I am slightly embarrassed to ask in c/cagrilintide · 29 points · 1 year ago
the co-agonism question is real and interesting
comment on genuine question about amylin that I am slightly embarrassed to ask in c/cagrilintide · 54 points · 1 year ago
Sceptical. If this were true we would see it reflected in the data and we do not.
comment on genuine question about amylin that I am slightly embarrassed to ask in c/cagrilintide · 1 points · 1 year ago
REDEFINE phase 2 readouts are interesting but 2 person CagriSema is different from 2 trial CagriSema.
1.8k
genuine question about amylin that I am slightly embarrassed to ask
Something I noticed reading old threads that I have not seen said out loud. The advice on REDEFINE in this community changed substantially around the start of last…
comment on stalled for 11 weeks at 2.5mg and I refuse to panic this time in c/orforglipron · 3 points · 1 year ago
cite ATTAIN/ACHIEVE arms specifically
comment on the STEP question that gets asked weekly, answered properly in c/trialwatch · 1 points · 1 year ago
Not convinced. The evidence does not support that reading.
comment on cagrilintide — my 24-week log, condensed into one table in c/cagrilintide · 17 points · 1 year ago
This is correct. The co-agonism is real.
comment on [Question] amylin — what am I missing here in c/cagrilintide · 1 points · 2 years ago
Strongly agree. REDEFINE is phase 24, not final.
comment on [Results] 77 weeks, 21kg, and endpoint was the hard part in c/trialwatch · 56 points · 2 years ago
off-label use data is different from approved-indication data
comment on [Results] 77 weeks, 21kg, and endpoint was the hard part in c/trialwatch · 0 points · 2 years ago
SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.
comment on 20 months in and non-peptide is still the thing I get wrong in c/orforglipron · 223 points · 2 years ago
the absorption problem is solved by non-peptide structure